OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

MC Genovese, A Lertratanakul, J Anderson, K Papp, W Tillett, F Van den Bosch, S Tsuji, E Dokoupilova, M Keiserman, X Wang

Research output: Other contribution

Original languageEnglish
PublisherBMJ Publishing Group Ltd
Publication statusPublished - 1 May 2020

Cite this